Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4′,5-trimethoxylstilbene-3′-O-phosphate disodium (M410)

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 300-311

  Cai, Yu Chen ^a   Zou, Yong ^b   Ye, Yan Li ^a   Sun, Hong Yi ^b   Su, Quan Guan ^a   Wang, Zhi Xin ^b   Zeng, Zhao Lei ^a   Xian, Li Jian ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU INSTITUTE OF CHEMISTRY   (China)

Author keywords

Hypoxia inducible factor 1; In vivo; Tubulin binding agent; Vascular disrupting agent

Indexed keywords

2 (3' BROMINE 4' METHOXYPHENYL) 3 (3',5' DIMETHOXYPHENYL)ACRYLIC ACID; 2 (3' HYDROXY 4' METHOXYPHENYL) 3 (3',5' DIMETHOXYPHENYL)ACRYLIC ACID; 2 (3' HYDROXY 4' METHOXYPHENYL)ACRYLIC ACID; 2 (4' METHOXYPHENYL) 3 (3',4',5' TRIMETHOXYPHENYL)ACRYLONITRILE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3' AMINO 3,4,4',5 TETRAMETHOXYDIHYDROSTILBENE; 3,4',5 TRIMETHOXYLSTILBENE 3' O PHOSPHATE SODIUM; CD31 ANTIGEN; CHLORDANE; COLCHICINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; M 295; M 314; M 317; M 330; M 393; MESSENGER RNA; STILBENE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DOWN REGULATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICROTUBULE ASSEMBLY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; CATTLE; CELL CYCLE; CELL DEATH; CELL MOTION; CHEMISTRY; COLON TUMOR; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; PATHOLOGY; POLYMERIZATION; TUMOR CELL LINE; UMBILICAL VEIN; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITORY CONCENTRATION 50; LIVER; MALE; MICE; POLYMERIZATION; STILBENES; TUBULIN; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957444495     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9366-x     Document Type: Article

References (42)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186
2. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3(2):177-182 (Pubitemid 27064702)
3. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363-1380 (Pubitemid 30660013)
4. Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13(1):31-36 (Pubitemid 21892580)
5. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92 (12):5510-5514
6. Levy AP, Levy NS, Wegner S, Goldberg MA (1995) Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270(22):13333-13340
7. Bunn HF, Poyton RO (1996) Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76(3):839-885 (Pubitemid 26286080)
8. Berra E, Milanini J, Richard DE, Le Gall M, Viñals F, Gothié E, Roux D, Pagès G, Pouysségur J (2000) Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 60 (8):1171-1178
9. Giordano FJ, Johnson RS (2001) Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 11 (1):35-40 (Pubitemid 32119275)
10. Semenza GL (2002) Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 41(2):79-83 (Pubitemid 34223708)
11. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1):9-22 (Pubitemid 29038270)
12. Josko J, Gwózdz B, Jedrzejowska-Szypulka H, Hendryk S (2000) Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 6(5):1047-1052
13. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45(2):209-211 (Pubitemid 19062390)
14. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N (1995) Antineoplastic agents 322. synthesis of Combretastatin A-4 prodrugs. Anticancer Drug Des 10(4):299-309
15. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-Day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21(23):4428-4438 (Pubitemid 46621821)
16. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59(7):1626-1634 (Pubitemid 29160136)
17. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57 (10):1829-1834 (Pubitemid 27209705)
18. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77(11):1761-1767 (Pubitemid 28254609)
19. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM (2001) The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61 (18):6811-6815 (Pubitemid 32896505)
20. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE (2001) Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7(4):1052-1060 (Pubitemid 32708745)
21. Griggs J, Brindle KM, Metcalfe JC, Hill SA, Smith GA, Beauregard DA, Hesketh R (2001) Potent anti-metastatic activity of combretastatin-A4. Int J Oncol 19(4):821-825
22. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21(15):2815-2822 (Pubitemid 46621828)
23. Zou Y, Wang ZX, Zhang XJ, Zhou Y, He SJ, Lin HZ Water soluble phosphate ester salt of (Z)-3'-hydroxy-3,4',5-trimethoxystilbene, and its preparation method, pharmaceutical composition and uses. Chinese Patent Office, ZL 200610033788.1
24. Zou Y, Xiao CF, Zhong RQ, Wei W, Huang WM, He SJ (2008) Synthesis of Combretastatin A-4 and Erianin. J Chem Res 6:354-356
25. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL (2002) Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 1(13):1191-1200
26. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61(17):6413-6422 (Pubitemid 32785286)
27. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81(8):1318-1327
28. Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM (2001) Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anti Canc Drugs 12(1):57-63 (Pubitemid 32142284)
29. Medarde M, Ramos AC, Caballero E, Peláez-Lamamié de Clairac R, López JL, Grávalos DG, Feliciano AS (1999) Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg Med Chem Lett 9 (16):2303-2308 (Pubitemid 29391511)
30. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E (1991) Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34(8):2579-2588
31. Nam NH, Kim Y, You YJ, Hong DH, Kim HM, Ahn BZ (2002) Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. Bioorg Med Chem Lett 12(15):1955-1958 (Pubitemid 34756457)
32. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21 (1A):93-102 (Pubitemid 32267629)
33. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62 (24):7247-7253 (Pubitemid 36025246)
34. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63(7):1534-1537 (Pubitemid 36373640)
35. Chaplin DJ, Pettit GR, Hill SA (1999) Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19(1A):189-195 (Pubitemid 29168237)
36. Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8(5):588-594 (Pubitemid 28477364)
37. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7(6):1661-1668 (Pubitemid 32708633)
38. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (22):5830-5835
39. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60(17):4693-4696
40. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G, Austrian Breast and Colorectal Cancer Study Group (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8(6):1831-1837 (Pubitemid 34633742)
41. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8(4 Suppl):S62-S67 (Pubitemid 34297081)
42. DachsGU, Steele AJ, Coralli C, Kanthou C, Brooks AC,Gunningham SP, Currie MJ, Watson AI, Robinson BA, Tozer GM (2006) Antivascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 6:280